Affiliation:
1. From Cardiovascular Research (M.H., G.C., N.B.), Physiology, University Zürich-Irchel, Switzerland; Cardiovascular Center (M.H., R.C., T.F.L., F.R.), Cardiology, University Hospital Zürich, Switzerland; Department of Clinical Research (S.S.), University Hospital Bern, Switzerland; German Cancer Research Center (DKFZ) (E.K., H.J.G.), Department of Cellular and Molecular Pathology, Heidelberg, Germany.
Abstract
In view of the ongoing controversy of cardiorenal safety of selective COX-2 inhibitors (coxibs), the present study was designed to examine the effects of 2 different coxibs, celecoxib and rofecoxib, compared with a traditional NSAID, diclofenac, and placebo on renal morphology and function in salt-sensitive hypertension. Salt-sensitive (DS) and salt-resistant (DR) Dahl rats were fed with NaCl-enriched diet (4% NaCl) for 8 weeks. Diclofenac (DS-diclofenac), rofecoxib (DS-rofecoxib), celecoxib (DS-celecoxib), or placebo was added to chow from weeks 6 to 8. Immunostaining for monocytes/macrophages (ED1) and cytotoxic T lymphocytes (CD8) was performed. In addition, renal morphology and proteinuria were assessed. Renal cortex mRNA was isolated for determination of COX-2, eNOS, and CRP mRNA by real-time reverse-transcriptase polymerase chain reaction. Untreated hypertensive animals showed glomerular injury including collapsing glomerulopathy, mesangial sclerosis, mesangiolysis, extracapillary proliferation, protein drops, and an especially high grade of glomerulosclerosis (
P
<0.05 versus DR-placebo) and CD8-positive and ED1-positive cells (
P
<0.01 versus DR-placebo), which was improved by celecoxib but not by diclofenac and rofecoxib. C-reactive protein mRNA in renal cortex was increased in DS-placebo animals (
P
<0.05 versus DR-placebo) and normalized by celecoxib (
P
<0.05 versus DS-placebo), whereas eNOS mRNA was decreased in the DS-rofecoxib group (
P
<0.05 versus DR-placebo, DS-celecoxib, and DS-diclofenac). Proteinuria was observed in hypertensive animals (
P
<0.0001 versus DR-placebo), increased by rofecoxib (
P
<0.05 versus DS-placebo), and normalized by celecoxib (
P
=0.0015 versus DS-placebo). This head-to-head comparison of selective and nonselective COX inhibitors demonstrates differential effects of coxibs on renal morphology and function in salt-dependent hypertension.
Publisher
Ovid Technologies (Wolters Kluwer Health)
Cited by
53 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献